OTCM
MATPF
Market cap23mUSD
, Last price
USD
Name
Maat Pharma SA
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
138.51%
Rev. 5Y
104.78%
Div Yld LY
—
Div Yld TTM
—
Revenues
5m
+40.67%
Net income
-31m
L+7.46%
CFO
-16m
L-27.80%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
Key people
Jean-Marie Lefevre
Chairman of the Board · since 2025
Eric Soyer
Chief Financial Officer · since 2024
Sian Crouzet
Chief Operations Officer
Sheri Simmons
Acting Chief Scientific Officer · since 2025
Jonathan Chriqui
Chief Business Officer · since 2024
Frederic Fasano
Chief Strategy and Corporate Development Officer · since 2025
Behzad Kharabi Masouleh
Acting Chief Medical Officer · since 2025
Gianfranco Pittari
Chief Medical Officer · since 2024
Claude Bertrand
Director
Dorothee Burkel
Director
Nadia Kamal
Director
Jean Volatier
Director
Herve Affagard
Chief Executive Officer, Co-Founder, Director
Headquarters & legal address
70 AVENUE TONY GARNIER
LYON 69007
FR
LYON 69007
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||